Previous 10 | Next 10 |
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced a str...
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc., and EXINI Diagnostics AB, and a global leader in the development, manufacture and commercialization of innovative diagnost...
Lantheus Holdings (LNTH), which merged with Progenics Pharmaceuticals (PGNX) in June, announces the filing of a U.S. marketing application seeking approval of PyL (18-F DCFPyL), a prostate-specific membrane antigen ((PSMA))-targeted positron emission tomography ((PET)) imaging agent for ...
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents a...
The following slide deck was published by Lantheus Holdings, Inc. in conjunction with this Read more ...
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and produ...
This article series shows every month a dashboard with aggregate industry metrics in healthcare (popular ETFs in this sector: XLV , IYH , IBB , XBI , VHT , XPH ). Shortcut If you are used to this dashboard series or if you are short on time, you can skip the first paragraphs and go...
The FDA approves Lantheus's ( LNTH -0.3% ) for VIALMIX RFID an activation device for DEFINITY injectable suspension, an intravenous ultrasound enhancing agent. More news on: Lantheus Holdings, Inc., Healthcare stocks news, Read more ...
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and produ...
Lantheus Holdings, Inc. (LNTH) Q2 2020 Results Earnings Conference Call July 30, 2020, 08:00 AM ET Company Participants Mark Kinarney - Senior Director, IR Mary Anne Heino - President and CEO Robert Marshall - CFO Conference Call Participants Raj Denhoy - Jefferies Larry ...
News, Short Squeeze, Breakout and More Instantly...
Lantheus Holdings Inc. Company Name:
LNTH Stock Symbol:
NASDAQ Market:
Lantheus Holdings Inc. Website:
2024-08-01 08:00:12 ET David Turkaly from JMP Securities issued a price target of $125.00 for LNTH on 2024-08-01 07:13:00. The adjusted price target was set to $125.00. At the time of the announcement, LNTH was trading at $104.83. The overall price target consensus is at...
Second Quarter 2024 Worldwide revenue of $394.1 million, an increase of 22.5% from second quarter 2023 Completed three strategic transactions to expand innovative pipeline GAAP fully diluted earnings per share of $0.88, compared to $1.33 in second quarter 2023. Adjusted fully ...
BEDFORD, Mass., July 17, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, July 31, 2024, to discuss its financial and operating results for the second...